RxDoctor Payments Data

Jennifer Randall

Psychiatric/Mental Health · Fort Myers, FLNPI 1447944954

Payments from drug & device makers

$4,566in general payments, 2019–2025

Across 292 payments — averaging $15.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$640
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$500
  • Alkermes, Inc.$437
  • Supernus Pharmaceuticals, Inc.$435
  • Neurocrine Biosciences, Inc.$359
  • Ironshore Pharmaceuticals Inc.$303
  • plus $2K from 16 others

What the payments were for

  • Food & beverage$4,52699%
  • Education$391%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,566 in reported general payments places this provider in the 85th percentile of 3,096 psychiatric/mental health providers in Florida.

See all psychiatric/mental health providers in Florida

Medicare billing

Part B allowed, 2024
$10,409
Medicare patients
30
Services billed
108

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CaplytaLumateperone Tosylate22$40,819
VraylarCariprazine Hcl17$23,951
RexultiBrexpiprazole12$22,977
Sertraline Hcl45$1,927
Duloxetine Hcl93$1,313
Lurasidone Hcl14$1,307
Buspirone Hcl73$894
Clonazepam86$712
Aripiprazole17$540
Mirtazapine29$471
Eszopiclone27$458
Olanzapine16$263
Quetiapine Fumarate24$255
Divalproex Sodium12$184
Escitalopram Oxalate13$175

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$500$40,81922 claims
AbbVieVraylar$640$23,95117 claims
Otsuka America Pharmaceutical, Inc.Rexulti$235$22,97712 claims
Almatica Pharma LLCSertraline Hcl$128$1,92745 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,096 psychiatric/mental health providers in Florida.

Other psychiatric/mental health in Fort Myers

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →